Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more

Recent & Breaking News (NDAQ:ATOS)

Atossa Genetics to Present at FSX San Francisco Investor Conference

Marketwired April 23, 2013

Atossa Genetics to Provide ForeCYTE Breast Health Test to Two Leading Breast Centers in Texas

Marketwired April 16, 2013

Atossa Genetics Launches Nationwide Awareness Program for Breast Cancer Prevention Test

Marketwired April 15, 2013

Atossa Genetics Announces $30 Million At-the-Market Common Stock Purchase Agreement With Aspire Capital, LLC

Marketwired March 28, 2013

Atossa Genetics Reports 2012 Results and Operating Highlights

Marketwired March 28, 2013

Free Research Reports on ATOS, EA, HNR and HPT Issued by the Bedford Report

Marketwired March 20, 2013

InvestorsGuru.com Filtered Mid-Day Market Movers Recap

Vivian Danielson March 17, 2013

Atossa Genetics Announces National Agreement With Network Provider FedMed

Marketwired March 13, 2013

Atossa Genetics to Present at the 25th Annual ROTH Conference

Marketwired March 6, 2013

Atossa Genetics Receives Warning Letter From the Food and Drug Administration

Business Wire February 25, 2013

Atossa Genetics to Present at the FSX Dallas Investor Conference

Marketwired February 5, 2013

Women With Dense Breasts Are at Higher Risk for Cancer

Marketwired February 4, 2013

Atossa Genetics to Present at the 15th Annual BIO CEO and Investor Conference

Marketwired January 28, 2013

Atossa Genetics, Inc. to Present at NINE 2013 - Noble Financial Capital Markets' Ninth Annual Equity Conference

Marketwired January 18, 2013

Atossa Genetics, Inc. to Present at the Personalized Medicine World Conference in Mountain View, California

Marketwired January 17, 2013

Atossa Genetics and Clarity Women's Health Announce U.S. Launch of the ForeCYTE Breast Health Test

Marketwired January 14, 2013

Atossa Genetics Names Kyle Guse as Chief Financial Officer, General Counsel and Secretary

Marketwired January 7, 2013

Atossa Genetics to Present at OneMedForum and Biotech Showcase

Marketwired January 3, 2013

Christopher S. Destro Joins Atossa Genetics as Vice President of Sales and Marketing

Marketwired December 21, 2012

Atossa Genetics Announces Third Quarter 2012 Financial Results

Marketwired December 20, 2012